ReviewAntibiotics (Basel, Switzerland)2021
Mutational Diversity in the Quinolone Resistance-Determining Regions of Type-II Topoisomerases of
Review in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 49 citations in OpenAlex.
- Article
- Presence of globally prominent multidrug-resistant genotypes ofMicrobial genomics · 2026Article
- Genomic epidemiology ofOne health (Amsterdam, Netherlands) · 2026Article
- Phage endolysin therapy: a modern antimicrobial strategy against highly drug-resistant superbugs.Archives of microbiology · 2026Review
- Gene Expression Analysis and Whole Genome Sequencing Reveal the Potential Mechanism of Ciprofloxacin Resistance in aVeterinary sciences · 2026Article
- Asymptomatic Carriage and Antimicrobial Resistance ofMicroorganisms · 2026Article
- Behavior ofInternational journal of food science · 2026Article
- Analysis of Multi-Antimicrobial Resistance Patterns in U.S. Foodborne Pathogens (2015-2025) Using Data from the NCBI Pathogen Isolates Browser.Pathogens (Basel, Switzerland) · 2025Article
- Prevalence and characterization of ciprofloxacin-resistantThe veterinary quarterly · 2025Article
- Mechanisms and Evolution of Antimicrobial Resistance in Ophthalmology: Surveillance, Clinical Implications, and Future Therapies.Antibiotics (Basel, Switzerland) · 2025Review
- Unveiling the Mechanisms of Bacterial Resistance and Countermeasures.Pathogens (Basel, Switzerland) · 2025Review
- Ciprofloxacin resistance and bile-induced biofilm enhancement inNew microbes and new infections · 2025Article
- Unveiling the Genetic Diversity and Antimicrobial Resistance Profiles of Salmonella Population From 2016 to 2020 in Thai Canal Water.Environmental microbiology reports · 2025Article
- Resistance Response and Regulatory Mechanisms of Ciprofloxacin-Induced ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Quinolone resistance inVeterinary world · 2025Article
- Computational identification of novel natural inhibitors against triple mutant DNA gyrase A in fluoroquinolone-resistantBiochemistry and biophysics reports · 2025Article
- Genetic characterization and in silico serotyping of 62 Salmonella enterica isolated from Korean poultry operations.BMC genomics · 2025Article
- Acquisition of novel antibiotic resistance genes by the bacterial predator Bacteriovorax sp. As-1.The ISME journal · 2025Article
- Antimicrobial resistance inScience in One Health · 2025Review
- Fluoroquinolone resistance in ESKAPE pathogens: evolutionary pathways, one health transmission, and clinical surveillance.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
Abstract
Quinolone resistance in bacterial pathogens has primarily been associated with mutations in the quinolone resistance-determining regions (QRDRs) of bacterial type-II topoisomerases, which are DNA gyrase and topoisomerase IV. Depending on the position and type of the mutation (s) in the QRDRs, bacteria either become partially or completely resistant to quinolone. QRDR mutations have been identified and characterized in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.